Leap Presents Biomarker Data from Study of DKN-01 Combo with Paclitaxel in Esophageal Cancer (MCUR)
Tweet Send to a Friend
Leap Therapeutics, Inc. reported updated clinical and biomarker data from an ongoing study of DKN-01, a monoclonal antibody against the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
